Ulrika Tehler

R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.

Journal: British journal of clinical pharmacology

Published: April 01, 2025

iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products.

iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products.

Journal: Molecular pharmaceutics

Published: March 13, 2025

World-wide-working-web: How to be successful on global teams.

World-wide-working-web: How to be successful on global teams.

Journal: Journal of pharmaceutical sciences

Published: April 28, 2024

iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.

iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug Products.

Journal: Molecular pharmaceutics

Published: December 07, 2023

Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model.

Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model.

Journal: Molecular pharmaceutics

Published: August 08, 2022

iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes.

iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes.

Journal: Molecular pharmaceutics

Published: May 24, 2022

iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.

iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.

Journal: Molecular pharmaceutics

Published: May 16, 2022

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 19, 2021

Hyaluronic Acid Hydrogels for Controlled Pulmonary Drug Delivery-A Particle Engineering Approach.

Hyaluronic Acid Hydrogels for Controlled Pulmonary Drug Delivery-A Particle Engineering Approach.

Journal: Pharmaceutics

Published: September 29, 2021

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers.

Journal: Drug design, development and therapy

Published: August 18, 2021

Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs.

Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs.

Journal: Journal of aerosol medicine and pulmonary drug delivery

Published: November 20, 2020

Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.

Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.

Journal: Molecular pharmaceutics

Published: May 29, 2020

Showing 1-12 of 18

Last Updated: 09/26/2026